Alterity Therapeutics Files 6-K for AGM Notice
Ticker: PRNAF · Form: 6-K · Filed: Oct 21, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 21, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agm, corporate-governance, filing-update
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K for its upcoming Annual General Meeting. Standard corporate update.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on October 21, 2025, to report its Notice of Annual General Meeting as Exhibit 99.1. The company, formerly known as Prana Biotechnology Ltd, is a development stage enterprise incorporated in Australia. This filing is being incorporated by reference into several of Alterity's existing registration statements on Forms S-8 and F-3.
Why It Matters
This filing indicates routine corporate governance activity for Alterity Therapeutics, including the scheduling of its Annual General Meeting, which is a key event for shareholder engagement and company oversight.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure regarding an upcoming meeting and does not contain new financial or operational information that would significantly alter the company's risk profile.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- Prana Biotechnology Ltd (company) — Former company name
- October 21, 2025 (date) — Filing date
- Form S-8 (document) — Incorporated by reference
- Form F-3 (document) — Incorporated by reference
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the Notice of Annual General Meeting as Exhibit 99.1.
When was this Form 6-K filed?
This Form 6-K was filed on October 21, 2025.
What is the former name of Alterity Therapeutics Limited?
The former name of Alterity Therapeutics Limited was Prana Biotechnology Ltd.
Which registration statements is this 6-K being incorporated by reference into?
This 6-K is being incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office address of Alterity Therapeutics Limited is Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-10-21 06:51:14
Filing Documents
- ea0261917-6k_alterity.htm (6-K) — 13KB
- ea026191701ex99-1_alterity.htm (EX-99.1) — 416KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- ex99-1_002.jpg (GRAPHIC) — 2KB
- ex99-1_003.jpg (GRAPHIC) — 23KB
- ex99-1_004.jpg (GRAPHIC) — 6KB
- ex99-1_005.jpg (GRAPHIC) — 980KB
- ex99-1_006.jpg (GRAPHIC) — 772KB
- 0001213900-25-100529.txt ( ) — 2906KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 21, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notice of Annual General Meeting/Proxy Form 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 21, 2025 2